COVID-19 Resources & Information

The COVID-19 pandemic uniquely affects patients who have rheumatologic and musculoskeletal diseases who take medications that alter the immune system. We know you’ve been following the news about coronavirus disease 2019 (COVID-19) and have questions and concerns about what this outbreak might mean for you. Below are brief answers, to the best of our knowledge, to some frequently asked questions regarding COVID-19.


When, with respect to onset of symptoms, is a person contagious?

Based on observations from family clusters in China and case reports elsewhere, it appears that a person is most contagious early in the disease and may be able to transmit the virus prior to the onset of symptoms.

How does the virus spread?

This virus originated in an animal reservoir and was transmitted to humans, with subsequent human-to-human spread. Community spread within the U.S. has occurred. This virus is spread through respiratory droplets produced when an infected person coughs or sneezes. It can also be transmitted on fomites, surfaces infected by a person with the disease. Convincing evidence of airborne transmission (which is distinct from droplet transmission) has not yet emerged with SARS-CoV-2.

What can patients do to protect themselves against contracting this disease?

The American College of Rheumatology has created the Essential Eight to provide guidance on minimizing your risk during this pandemic.

What else can patients and their providers do?

Please be certain that your patients have received all appropriate vaccinations, including seasonal influenza, pneumonia, pertussis, and shingles vaccines. These will not prevent COVID-19 but may lessen the chance of a secondary infection and will prevent illnesses that could be confused with COVID-19. Patients should employ frequent handwashing and in general avoid touching their face or mucous membranes.

In addition, patients should be advised to keep ample stocks (e.g., one-month supply) of necessary medications on hand in case they are prevented from refilling prescriptions in a timely manner.

Should patients who are taking prednisone, DMARDs, or other drugs for their rheumatic diseases stop them?

All patients should talk to their rheumatologist or rheumatology professional prior to discontinuing any of their medications. While there are no data on the influence of these medications on COVID-19, providers should follow their current practice for interrupting therapy during episodes of infection.

What is the spectrum of disease and what is the estimate of mortality associated with COVID-19?

The disease can range from a very mild flu-like illness with upper respiratory symptoms, to severe pneumonia and ARDS. Symptoms generally appear 2-14 days after exposure and include:

  • Fever
  • Cough
  • Shortness of breath

Mortality estimates are currently at 1-2% among groups of patients with clinically evident disease. This is higher than seasonal influenza, but lower than prior coronavirus epidemics. Also, there are likely patients with few or no symptoms who do not get diagnosed with COVID, and thus, the true mortality rate may be lower.

What is known about the rate and severity of infection in patients with rheumatologic disease, especially those patients taking prednisone, DMARDs, biologics, or other immunosuppressive agents?

Currently, there are no specific data on SARS-CoV-2 in patients with rheumatologic disease or immunosuppression.


COVID-19 Resources

COVID-19: What You Need to Know

CDC: Testing for Coronavirus

Find a COVID-19 Test Center

50 State Health Department COVID-19 Resources

John Hopkins Coronavirus Interactive Map

Hydroxychloroquine (Plaquenil) Patient Fact Sheet